We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akome’s proprietary cGMP drug formulations comprising psychedelic compounds and plant bioactives distinguish its approach on the psychedelic treatment of neurological disorders from other companies.